We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of JR-141 in Patients With Mucopolysaccharidosis II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03568175
Recruitment Status : Completed
First Posted : June 26, 2018
Last Update Posted : November 14, 2022
Sponsor:
Information provided by (Responsible Party):
JCR Pharmaceuticals Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and safety of study drug for the treatment of the MPS II.

Condition or disease Intervention/treatment Phase
Mucopolysaccharidosis II Drug: JR-141 Phase 2 Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II
Actual Study Start Date : August 1, 2018
Actual Primary Completion Date : February 20, 2020
Actual Study Completion Date : February 20, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: JR-141 2.0 mg/kg/week Drug: JR-141
IV infusion, 2.0 mg/kg/week


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid [ Time Frame: Baseline to 52 weeks ]

Secondary Outcome Measures :
  1. Change From Baseline in Serum Heparan Sulfate Levels. [ Time Frame: Baseline, 24-26 weeks, 50-52 weeks ]
  2. Change From Baseline in Serum Dermatan Sulfate Levels. [ Time Frame: Baseline, 24-26 weeks, 50-52 weeks ]
  3. Change From Baseline in Urinary Heparan Sulfate Levels. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  4. Change From Baseline in Urinary Dermatan Sulfate Levels. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  5. Change From Baseline in Liver Volumes. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  6. Change From Baseline in Spleen Volumes. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  7. Change From Baseline in Cardiac Function. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  8. Change From Baseline in 6-minute Walk Test Distance. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
    Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test

  9. Change From Baseline in Joint Range of Motion. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  10. Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid. [ Time Frame: Baseline to 25 weeks ]
  11. Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid. [ Time Frame: Baseline, 25 weeks, 52 weeks ]
  12. Change from Baseline in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001) [ Time Frame: 25, 52 weeks ]
  13. Change from Baseline in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. ) [ Time Frame: 25, 52 weeks ]
  14. Drug concentration in Cerebrospinal Fluid. [ Time Frame: 25, 52*weeks ]
    *Drug concentration in Cerebrospinal Fluid at 52 Weeks is applicable only for subjects to be enrolled in extension study .


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capable of providing written consent by himself (not mandatory for those aged under 20 years at the time of informed consent process, or those who is impossible to obtain consent from the patient himself due to intellectual disabilities associated with MPS II.)
  2. In the case of a patient who is under the age of 20 years or from whom it is not possible to obtain consent due to intellectual disabilities associated with MPS II, he may be included if written consent can be provided by legal representative (however, written consent should be obtained from the patient himself too, whenever possible)
  3. Males with confirmed diagnosis of MPS II, based on deficient activity of iduronate-2-sulfatase (IDS) in leucocytes, plasma or fibroblasts and/or pathogenic mutations identified in the IDS gene, etc.
  4. Naïve patients or patients who are receiving stable enzyme replacement therapy with Elaprase for more than 8 weeks before the observational period starts.

Exclusion Criteria:

  1. Previous engrafted HSCT, excluding those who need enzyme replacement therapy even after HSCT.
  2. Judged by the investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely experience difficulty breathing during the lumbar puncture process.
  3. Judged by the investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity.
  4. Patients who have received other investigational product within 4 months before enrollment in the study.
  5. Otherwise judged by the investigator or subinvestigator to be ineligible to participate in the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03568175


Locations
Show Show 19 study locations
Sponsors and Collaborators
JCR Pharmaceuticals Co., Ltd.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: JCR Pharmaceuticals Co., Ltd.
ClinicalTrials.gov Identifier: NCT03568175    
Other Study ID Numbers: JR-141-301
First Posted: June 26, 2018    Key Record Dates
Last Update Posted: November 14, 2022
Last Verified: November 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidosis II
Mucopolysaccharidoses
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Mucinoses
Connective Tissue Diseases
 Metabolic Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System